Effect of chemotherapy on whole-blood cytokine responses to Mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis

Clinical and Vaccine Immunology

Volumn 18, Issue 8, 2011, Pages 1378-1386

  Bertholet, Sylvie ^a,d   Horne, David J ^b   Laughlin, Elsa M ^a   Savlov, Margery ^b   Tucakovic, Ines ^a   Coler, Rhea N ^a   Narita, Masahiro ^b,c   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CYTOKINE; EARLY SECRETORY ANTIGENIC TARGET 6; ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; ISONIAZID; MYCOBACTERIUM ANTIGEN; PROTEIN ESAT 70; PYRAZINAMIDE; RECOMBINANT PROTEIN; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; TREATMENT RESPONSE;

ADULT; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BLOOD; CYTOKINES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 79961108145     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05037-11     Document Type: Article

References (43)

1. Aiken, A. M., et al. 2006. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect. Dis. 6:66.
2. Al-Attiyah, R., et al. 2006. Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens of Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 47:254-261. (Pubitemid 43881745)
3. Al-Attiyah, R., A. S. Mustafa, A. T. Abal, N. M. Madi, and P. Andersen. 2003. Restoration of mycobacterial antigen-induced proliferation and interferon-gamma responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy. FEMS Immunol. Med. Microbiol. 38:249-256. (Pubitemid 37289749)
4. Barry, S. M., M. C. Lipman, B. Bannister, M. A. Johnson, and G. Janossy. 2003. Purified protein derivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J. Infect. Dis. 187:243-250. (Pubitemid 36132637)
5. Bertholet, S., et al. 2008. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181:7948-7957.
6. Biselli, R., et al. 2010. Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin. Microbiol. Infect. 16:1282-1284.
7. Blumberg, H. M., et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
8. Carrara, S., et al. 2004. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin. Infect. Dis. 38:754-756. (Pubitemid 38333874)
9. Chee, C. B., et al. 2007. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am. J. Respir. Crit. Care Med. 175:282-287. (Pubitemid 46203133)
10. Dheda, K., et al. 2007. Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. J. Infect. 55:169-173. (Pubitemid 47029747)
11. Dheda, K., Z. F. Udwadia, J. F. Huggett, M. A. Johnson, and G. A. Rook. 2005. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr. Opin. Pulm. Med. 11:195-202. (Pubitemid 40577168)
12. Diel, R., R. Loddenkemper, and A. Nienhaus. 2010. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 137:952-968.
13. Doherty, T. M., et al. 2005. Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J. Immunol. Methods 298:129-141. (Pubitemid 40545099)
14. Dominguez, J., et al. 2009. T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagn. Microbiol. Infect. Dis. 63:43-51.
15. Eum, S. Y., et al. 2010. Association of antigen-stimulated release of tumor necrosis factor-alpha in whole blood with response to chemotherapy in patients with pulmonary multidrug-resistant tuberculosis. Respiration 80:275-284.
16. Ferrand, R. A., G. H. Bothamley, A. Whelan, and H. M. Dockrell. 2005. Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after anti-tuberculosis treatment. Int. J. Tuberc. Lung Dis. 9:1034-1039. (Pubitemid 41549192)
17. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129. (Pubitemid 32368031)
18. Handzel, Z. T., et al. 2007. Increased Th1 and Th2 type cytokine production in patients with active tuberculosis. Isr. Med. Assoc. J. 9:479-483. (Pubitemid 46979155)
19. Harari, A., et al. 2011. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 17:372-376.
20. Herrmann, J. L., et al. 2009. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS One 4:e4130.
21. Hirsch, C. S., et al. 2001. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J. Infect. Dis. 183:779-788. (Pubitemid 32171753)
22. Horne, D. J., et al. 2010. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10:387-394.
23. Hussain, R., et al. 2002. Cytokine profiles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population. J. Immunol. Methods 264:95-108. (Pubitemid 34615896)
24. Hussain, R., N. Talat, F. Shahid, and G. Dawood. 2007. Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development. Clin. Vaccine Immunol. 14:1578-1586.
25. Jalapathy, K. V., C. Prabha, and S. D. Das. 2004. Correlates of protective immune response in tuberculous pleuritis. FEMS Immunol. Med. Microbiol. 40:139-145. (Pubitemid 38249538)
26. Katiyar, S. K., A. Sampath, S. Bihari, M. Mamtani, and H. Kulkarni. 2008. Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:1146-1152.
27. Kobashi, Y., et al. 2009. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J. Infect. 58:197-204.
28. Lalvani, A., et al. 2001. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J. Infect. Dis. 183:469-477. (Pubitemid 32105605)
29. Leyten, E. M., et al. 2006. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 8:2052-2060. (Pubitemid 44311602)
30. Millington, K. A., et al. 2007. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J. Immunol. 178:5217-5226. (Pubitemid 46595306)
31. Pai, M., et al. 2007. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection 35:98-103. (Pubitemid 46536774)
32. Pai, M., L. W. Riley, and J. M. Colford, Jr. 2004. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4:761-776.
33. Pathan, A. A., et al. 2001. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J. Immunol. 167:5217-5225. (Pubitemid 33009758)
34. Ribeiro, S., et al. 2009. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect. Dis. 9:23.
35. Ribeiro-Rodrigues, R., et al. 2002. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin. Diagn. Lab. Immunol. 9:818-823. (Pubitemid 34773884)
36. Sauzullo, I., et al. 2009. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One 4:e5187.
37. Snider, D. E., Jr. 1985. Bacille Calmette-Guerin vaccinations and tuberculin skin tests. JAMA 253:3438-3439.
38. Ulrichs, T., R. Anding, S. H. Kaufmann, and M. E. Munk. 2000. Numbers of IFN-gamma-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy. Int. J. Tuberc. Lung Dis. 4:1181-1183. (Pubitemid 32046299)
39. Vankayalapati, R., et al. 2003. Serum cytokine concentrations do not parallel Mycobacterium tuberculosis-induced cytokine production in patients with tuberculosis. Clin. Infect. Dis. 36:24-28. (Pubitemid 36099092)
40. Veenstra, H., et al. 2007. Changes in the kinetics of intracellular IFNgamma production in TB patients during treatment. Clin. Immunol. 124:336-344. (Pubitemid 47260591)
41. Vekemans, J., et al. 2001. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect. Immun. 69:6554-6557. (Pubitemid 32885227)
42. WHO. 2007. Global tuberculosis control: surveillance, planning, financing, vol. 376. World Health Organization, Geneva, Switzerland.
43. Wu-Hsieh, B. A., et al. 2001. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin. Infect. Dis. 33:1336-1340. (Pubitemid 32955183)